Oral GLP-1 drugs could widen access, but high prices may do the opposite
Oral GLP-1 medicines are moving rapidly into obesity care, while companies invest billions in manufacturing and compete across weight loss, diabetes and broader cardiometabolic outcomes.…
Oral GLP-1 drugs could widen access, but high prices may do the opposite
GLP-1 drugs can reduce adolescent obesity. Who will pay for years of treatment?
Boehringer Ingelheim is adding a third target to obesity treatment.
IPM Brief – Issue 15 | The Shortcut Trap: Why Policy Announcements Do Not Reach Patients
Stroke Recovery Needs More Than Scans and Scores
Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.
The Cyclospora Test Was Wrong. Public Trust Cannot Be
Explore by disease area
Cardiology
Mapping prevention, diagnostics and access pathways for cardiovascular care.
Cardiometabolic
Tracking risk, prevention and access in metabolic and vascular health.
Eye Disease
Following diagnostics, treatment access and equity in vision care.
Infectious disease
Tracking diagnostics, resistance, prevention and access across infection pathways.
Neurology
Mapping early diagnosis, biomarkers and access in brain health.
Oncology
Following testing, treatment access and equity across cancer pathways.
Alerts
See all →
GLP-1 drugs can reduce adolescent obesity. Who will pay for years of treatment?
The Cyclospora Test Was Wrong. Public Trust Cannot Be
A Breast-Cancer Warning Is Hiding in Aggregated Data
New York Had Cooling-Tower Rules. Legionnaires’ Still Broke Through.
ctDNA Is Becoming the New Argument Over Chemotherapy
India Approved Its First Dengue Vaccine. Access Is Still Unwritten.
Myeloma Patients May Not Need Treatment Forever
Canada Chose An Ebola Travel Ban. WHO Warned Against It.
Lung Cancer May Be Entering the Chemo-Replacement Fight
Britain Has A £1 Billion Pandemic Plan.
Signals
See all →
Boehringer Ingelheim is adding a third target to obesity treatment.
Alzheimer’s Pill Has Finished the Trial. Evidence Has Not.
Oral GLP-1 drugs could widen access, but high prices may do the opposite
Oral GLP-1 medicines are moving rapidly into obesity care, while companies invest billions in manufacturing and compete across weight loss, diabetes and broader cardiometabolic outcomes.…
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
By subscribing, you agree to receive updates from IPM Alliance. You can unsubscribe at any time. For more information, please see our Privacy Policy.
